Поиск биомаркеров немелкоклеточного рака легкого: показатели воспаления и клеточной адгезии для диагностики и прогнозирования возврата заболевания

Цель. Проанализировать данные об использовании биомаркеров воспалительного ответа и клеточной адгезии в диагностике и прогнозировании возврата заболевания при немелкоклеточном раке легкого.

Результаты. В обзоре анализируются данные об использовании клеток крови, продуцируемых ими цитокинов CXCL5, CXCL8, рецепторов для них CXCR1, CXCR2, рецептора клеточной адгезии (CD44v6) и С-реактивного белка в качестве диагностических и прогностических биомаркеров возврата заболевания при немелкоклеточном раке легкого. Показаны перспективность этого направления и имеющиеся недостатки.

Выводы. Для улучшения диагностики и прогнозирования безрецидивной выживаемости немелкоклеточного рака легкого перспективным является комплексное определение цитокинов, их рецепторов – участников воспалительного ответа организма на развивающуюся опухоль, и рецептора CD44v6, отобранных на основе множественного регрессионного анализа.

1. Grivennikov, S. I., Greten F. R., Karin M. Immunity, inflammation, and cancer // Cell. – 2010. – Vol. 140, № 6. – P. 883–99. – doi: 10.1016/j.cell.2010.01.025.

2. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer / R. M. Bremnes, L. T. Busund, T. L. Kilvær [et al.] // Thorac Oncol. – 2016. – № 11(6). – Р. 789–800. – doi: 10.1016/j.jtho.2016.01.015.

3. Cancer-related inflammation / A. Mantovani, P. Allavena, A. Sica [et al.] // Nature. – 2008. – Vol. 454, № 7203. – P. 436–44. – doi: 10.1038/nature07205.

4. An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer / A. Mishra, K. H. Suman, N. Nair [et al.] // Molecular Biology Reports. – 2021. – Vol. 48, № 9. – P. 6551–6561. – doi: 10.1007/s11033-021-06648-8.

5. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immunecheckpoint inhibitors / K. A. Schalper, M. Carleton, M. Zhou [et al.] // Nature Medicine. – 2020. – Vol. 26, № 5. – P. 688–692. – doi: 10.1038/s41591-020-0856-x.

6. Ha, H. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases / H. Ha, B. Debnath, N. Neamati // Theranostics. – 2017. – Vol. 7, № 6. – Р. 1543–1588. – doi: 10.7150/thno.15625.

7. Serum chemokine CXCL8 is a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19–9 and CEA / A. Litman-Zawadska, M. Łukaszewicz-Zając, M. Gryko [et al.] // Polish archives of internal medicine. – 2018. – Vol. 128, № 9. – P. 524–531. – doi: 10.7150/thno.15625.

8. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer / R. W. Veltri, M. C. Miller, G. Zhao [et al.] // Urology. – 1999. – Vol. 53, № 1. – P. 139–147. – doi: 10.1016/s0090-4295(98)00455-5.

9. Validation and clinicopathologic associations of a urinebased bladder cancer biomarker signature / G. Zhang, E. GomesGiacoia, Y. Dai [et al.] // Diagnostic Pathology. – 2014. – Vol. 9. – P. 200–209. – doi: 10.1186/s13000-014-0200-1.

10. Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients / M. Łukaszewicz-Zając, S. Pączek, P. Muszyński [et al.] // Clinical and Experimental Medicine. – 2019. – Vol. 19, № 2. – P. 191–199. – doi: 10.1007/s10238-019-00548-9.

11. Expression of CXCL8 and its relationship with prognosis in patients with non-small cell lung cancer / X. Ma, X. Zhu, M. Zou [et al.] // American Journal of Cancer Research. – 2024. – Vol. 14, № 6. – P. 2934–2945. – doi: 10.62347/LJDQ3897.

12. DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis / Q. Liu, A. Li, S. Yu [et al.] // Journal of Hematology and Oncology. – 2018. – Vol. 11, № 1. – 53. – doi: 10.1186/s13045-018-0597-1.

13. Sepuru, K. M. Solution structure of CXCL5-a novel chemokine and adipokine implicated in inflammation and obesity / K. M. Sepuru, K. M. Poluri, K. Rajarathnam // PLoS One. – 2014. – Vol. 9, № 4. – Р. e93228. – doi: 10.1371/journal.pone.0093228.

14. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer / C. Chen, Z. Q. Xu, Y. P. Zong [et al.] // Cell Death and Disease. – 2019. – Vol. 10, № 3. – Р. 178. – doi: 10.1038/s41419-019-1431-6.

15. DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling / N. Han, X. Yuan, H. Wu [et al.] // Oncotarget. – 2015. – Vol. 6, № 8. – Р. 877–888. – doi: 10.18632/oncotarget.3463.

16. Prognostic value of hyaluronan expression in non-smallcell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma / R. Pirinen, R. Tammi, M. Tammi [et al.] // International Journal of Cancer. – 2001. – Vol. 95, № 1. – P. 12–17. – doi: 10.1002/1097-0215(20010120)95:1<12::aid-ijc1002>3.0.co;2-e.

17. Diagnostic value of circulating CXC chemokines in nonsmall cell lung cancer / A. Sparks, I. Jaunalksne, I. Spaka [et al.] // Anticancer Research. – 2015. – Vol. 35, № 12. – P. 6979–6983.

18. CXCL5 as a potential novel prognostic factor in earlystage non-small cell lung cancer: results of a study of expression levels of 23 genes / O. Kowalczuk, T. Burzykowski, W. Niklinska [et al.] // Tumour Biology. – 2014. – Vol. 35, № 5. – Р. 4619– 4628. – doi: 10.1007/s13277-014-1605-x.

19. Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer / J. Deng, X. Ma, Y. Ni [et al.] // Cancer Medicine. – 2022. – Vol. 11, № 8. – P. 1787–1795. – doi: 10.1002/cam4.4567.

20. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer / M. Nassar, S. K. Raghuwanshi, D. J. Grant [et al.] // Journal of Immunology. – 2009. – Vol. 183, № 5. – P. 3425–3432. – doi: 10.4049/jimmunol.0900305.

21. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue / O. Oladipo, S. Conlon, A. O’Grady [et al.] // British journal of cancer. – 2011. – Vol. 104, № 3. – P. 480–487. – doi: 10.1038/sj.bjc.6606055.

22. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer / M. Xue, J. Liu, L. Su [et al.] // Oncotarget. – 2017. – Vol. 8, № 30. – P. 48930–48937. – doi: 10.18632/oncotarget.16893.

23. Chu, H. C-X-C motif chemokine receptor type 2 correlates with higher disease stages and predicts worse prognosis, and its downregulation enhances chemotherapy sensitivity in triple-negative breast cancer / H. Chu, W. Li, H. Li // Translational Cancer Research. – 2020. – Vol. 9, № 2. – P. 840–848. – doi: 10.21037/tcr.2019.12.38.

24. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma / P. Saintigny, E. Massarelli, S. Lin [et al.] // Cancer research. – 2013. – Vol. 73, № 2. – P. 571–582. – doi: 10.1158/0008-5472.CAN-12-0263.

25. Loss of β-arrestin-2 and activation of CXCR2 correlate with lymph node metastasis in non-small cell lung cancer / L. Cong, Z. Y. Qiu, Y. Zhao [et al.] // Journal of cancer. – 2017. – Vol. 8, № 14. – P. 2785–2792. – doi: 10.7150/jca.19631.

26. Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma / Y. Lui, B. Wu, H. Geng [et al.] // Oncology Letters. – 2015. – Vol. 10, № 3. – Р. 1315–1322. – doi: 10.3892/ol.2015.3402.

27. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells / Y. M. Zhu, S. Webster, D. Flower [et al.] // British Journal of Cancer. – 2004. – Vol. 91, № 11. – P. 1970–1976. – doi: 10.1038/sj.bjc.6602227.

28. Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer / C. M. Ohri, A. Shikotra, R. H. Green [et al.] // BMC Cancer. – 2010. – Vol. 10. – Р. 172. – doi: 10.1186/1471-2407-10-172.

29. Agassandian, M. C-reactive protein and lung diseases / M. Agassandian, G. V. Shurin Ma Y., M. R. Shurin // International Journal of Biochemistry and Cell Biology. – 2014. – Vol. 53. – P. 77–88. – doi: 10.1016/j.biocel.2014.05.016.

30. Role of C reactive protein in non-small cell lung cancer staging / J. A. Torrecilla, S. Scrimini, J. Sauleda [et al.] // European Respiratory Journal. – 2011. – Vol. 38, suppl. 55. – P. 2806. – doi: 10.1183/13993003/erj.38.Suppl_55.p2806.

31. Aref, H. CRP evaluation in non-small cell lung cancer / H. Aref, S. Refaat // Egyptian Journal of Chest Diseases and Tuberculosis. – 2014. – Vol.63, № 3. – P. 717–772. – doi: 10.1016/j.ejcdt.2014.02.003.

32. Tumor-infiltrating platelets promote the growth of lung adenocarcinoma / X. Li, M. Li, Z. Hu [et al.] // Translational Oncology. – 2024. – Vol. 39. – Р. 101813. – doi: 10.1016/j.tranon.2023.101813.

33. The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer / H. Xie, G. Ruan, L. Wei [et al.] // Journal of Cachexia Sarcopenia and Muscle. – 2023. – Vol. 14, № 2. – P. 869–878. – doi: 10.1002/jcsm.13199.

34. The Role of Macrophages in Cancer Development and Therapy / E. Cendrowicz, Z. Sas, E. Bremer, T. P. Rygiel // Cancers (Basel). – 2021. – Vol. 13, № 8. – Р. 1946. – doi: 10.3390/cancers13081946.

35. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity / E. S. White, S. R. Strom, N. L. Wys, D. A. Arenberg // Journal of Immunology – 2001. – Vol. 166, № 12. – P. 7549–7555. – doi: 10.4049/jimmunol.166.12.7549.

36. Zhou, J. Role of tumor associated neutrophils in lung cancer (Review) / J. Zhou, H. Liu, S. Jiang, W. Wang // Oncology Letters. – 2023. – Vol. 25, № 1. – Р. 2. – doi: 10.3892/ol.2022. 13588.

37. Schlesinger, M. Role of platelets and platelet receptors in cancer metastasis / M. Schlesinger // Journal of Hematology and Oncology. – 2018. – Vol. 11, № 1. – Р. 125. – doi: 10.1186/s13045-018-0669-2.

38. Lymphocyte percentage as a valuable predictor of prognosis in lung cancer / H. Huang, L. Li, W. Luo [et al.] // Journal of Cellular and Molecular Medicine. – 2022. – Vol. 26, № 7. – P. 1918–1931. – doi: 10.1111/jcmm.17214.

39. Elevations of monocyte and neutrophils, and higher levels of granulocyte colony-stimulating factor in peripheral blood in lung cancer patients / W. Yin, J. Lu, Y. Yao [et al.] // Thoracic Cancer. – 2021. – Vol. 12, № 20. – P. 2680–2690. – doi: 10.1111/1759-7714.14103.

40. Platelet count predicts prognosis in operable non-small cell lung cancer / D. Yu, B. Liu, L. Zhang, K. Du // Experimental and Therapeutic Medicine. – 2013. – Vol. 5, № 5. – P. 1351– 1354. – doi: 10.3892/etm.2013.1003.

41. Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients / Y. Ji, L. Sheng, X. Du [et al.] // Platelets. – 2015. – Vol. 26, № 2. – P. 138–142. – doi: 10.3109/09537104.2014.888547.

42. Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer / M. Alifano, P. E. Falcoz, V. Seegers [et al.] // Journal of Thoracic and Cardiovascular Surgery. – 2011. – Vol. 142, № 5. – P. 1161–1167. – doi: 10.1016/j.jtcvs.2011.07.021.

43. Miao, S. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors /s. Miao, B. L. Rodriguez, D. L. Gibbons // Cancers (Basel). – 2024. – Vol. 16, № 14. – Р. 2507. – doi: 10.3390/cancers16142507.

44. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer / D. J. Pinato, R. J. Shiner, M. J. Seckl [et al.] // British Journal of Cancer. – 2014. – Vol. 110, № 8. – P. 1930–1935. – doi: 10.1038/bjc.2014.145.

45. Masoud, G. HIF-1α pathway: role, regulation and intervention for cancer therapy / G. Masoud, L. Wei // Acta Pharmacologica Sinica. – 2015. – Vol. 5, № 5. – P. 378–389. – doi: 10.1016/j.apsb.2015.05.007.

46. Heider, K. H. CD44v6: a target for antibody-based cancer therapy / K. H. Heider // Cancer Immunology and Immunotherapy. – 2004. – Vol. 53, № 7. – P. 567–579. – doi: 10.1007/s00262-003-0494-4.

47. Expression of CD44 abnormal transcripts in human gastric carcinomas / H. Yokozaki, R. Ito, H. Nakayama [et al.] // Cancer Letters. – 1994. – Vol. 83, № 1-2. – P. 229–234. – doi: 10.1016/0304-3835(94)90324-7.

48. The biology and role of CD44 in cancer progression: therapeutic implications / C. Chen, S. Zhao, A. Karnad, J. W. Freeman // Journal of Hematology and Oncology. – 2018. – Vol. 11, № 1. – Р. 64. – doi: 10.1186/s13045-018-0605-5.

49. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients / Z. Li, K. Chen, P. Jiang [at al.] // Diagnostic Pathology. – 2014. – Vol. 9. – Р. 79. – doi: 10.1186/1746-1596-9-79.

50. CD44v6 acts as a directional responding factor in the process of transcoelomic metastasis from gastric carcinoma to Krukenberg tumor / Z. Zhou, C. Li, Z. Wang [et al.] // Expert Review of Molecular Diagnostics. – 2023. – Vol. 23, № 7. – P. 583–588. – doi: 10.1080/14737159.2023.2223981.

51. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer / T. Miyoshi, K. Kondo, N. Hino [et al.] // Clinical cancer research. – 1997. – Vol. 8. – P. 1289–1297.

52. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors / A. M. Afify, S. Tate, B. Durbin-Johnson [et al.] // International Journal of Biological Markers. – 2011. – Vol. 26, № 1. – P. 50–57. – doi: 10.5301/jbm.2011.6291.

53. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors / Z. Zhang, F. Yuan, R. Chen [et al.] // Frontiers in Immunology. – 2020. – Vol. 11. – Р. 1173. – doi: 10.3389/fimmu.2020.01173.

54. Prognostic Value of Serum Tumor Markers in Patients with Stage III NSCLC Treated With Chemoradiotherapy / T. Tokito, K. Azuma, K. Yamada [et al.] // In Vivo. – 2019. – Vol. 33, № 3. – P. 889–895. – doi: 10.21873/invivo.11555.

55. Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma / Y. He, Y. Cui, D. Chang, T. Wang // Oncotarget. – 2017. – Vol. 84, № 2. – P. 73115–73122. – doi: 10.18632/oncotarget.17611.

56. The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis / R. Fang, Y. Zhu, V. S. Khadka [et al] // Frontiers in Physiology. – 2018. – Vol. 9. – Р. 1710. – doi: 10.3389/fphys.2018.01710.

57. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? / M. Plebani, D. Basso, F. Navaglia [et al.] // British Journal of Cancer. – 1995. – Vol. 72, № 1. – P. 170–173. – doi: 10.1038/bjc.1995.296.

58. Wang, W. What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients / W. Wang, H. Liu, G. Li // Frontiers in Endocrinology (Lausanne). – 2022. – Vol. 13. – Р. 947443. – doi: 10.3389/fendo.2022.947443.

59. Kumar, S., Logistic regression in cancer research: A narrative review of the concept, analysis, and interpretation /s. Kumar, V. Gota // Cancer Research, Statistics and Treatment. – 2023. – Vol. 6, № 4. – P. 573–578. – doi: 10.4103/crst.crst_293_23.

60. Early Lung Cancer Prediction using Correlation and Regression / K. Sivanagireddy, S. Yerram, S. S. N. Kowsalya [et al.] // International Conference on Computer, Power and Communications (ICCPC). – 2022. – P. 24–28. – doi:10.1109/ICCPC55978. 2022.10072059.